Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is characterized by the accumulation of fibrillar collagens in the alveolar space resulting in reduced pulmonary function and a high mortality rate. Biomarkers measuring the turnover of type I and III collagen could provide valuable information for prognosis and treatment decisions in IPF. Methods: Serological biomarkers reflecting the formation of type III collagen (PRO-C3) and degradation of type I (C1M) and III collagen (C3M) were evaluated in a real-world cohort of 178 newly diagnosed IPF patients. Blood samples and clinical data were collected at baseline, six, and 12 months. Baseline and longitudinal biomarker levels were related to disease progression of IPF (defined as ≥ 5% decline in forced vital capacity (FVC) and/or ≥ 10% decline in diffusing capacity for carbon monoxide (DLco) and/or all-cause mortality at 12 months). Furthermore, we analysed differences in percentage change of biomarker levels from baseline between patients receiving antifibrotic treatment or not. Results: Increased baseline levels of type I and III collagen turnover biomarkers were associated with a greater risk of disease progression within 12 months compared to patients with a low baseline type I and III collagen turnover. Patients with progressive disease had higher serum levels of C1M (P = 0.038) and PRO-C3 (P = 0.0022) compared to those with stable disease over one year. There were no differences in biomarker levels between patients receiving pirfenidone, nintedanib, or no antifibrotics. Conclusion: Baseline levels of type I and III collagen turnover were associated with disease progression within 12 months in a real-world cohort of IPF patients. Longitudinal biomarker levels of type I and III collagen turnover were related to progressive disease. Moreover, antifibrotic therapy did not affect type I and III collagen turnover biomarkers in these patients. PRO-C3 and C1M may be potential biomarkers for a progressive disease behavior in IPF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Jenkins, R. G., Simpson, J. K., Saini, G., Bentley, J. H., Russell, A.-M., Braybrooke, R., Molyneaux, P. L., McKeever, T. M., Wells, A. U., Flynn, A., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00048-x · Cited by 314
Self-citationOrgan, L. A., Duggan, A.-M. R., Oballa, E., Taggart, S. C., Simpson, J. K., Kang’ombe, A. R., Braybrooke, R., Molyneaux, P. L., North, B., Karkera, Y., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1118-7 · Cited by 139
Self-citation
Cited by
Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D., Renna, H. A., Agarwala, P., Spiegler, P., DeLeon, J., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 314
Savin, I. A., Zenkova, M. A., & Sen’kova, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314959 · Cited by 279
Regional and disease specific human lung extracellular matrix composition
Hoffman, E. T., Uhl, F. E., Asarian, L., Deng, B., Becker, C., Uriarte, J. J., Downs, I., Young, B., & Weiss, D. J. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2022.121960 · Cited by 64
The role of precision medicine in interstitial lung disease
Maher, T. M., Nambiar, A. M., & Wells, A. U. (2022) · European Respiratory Journal · doi:10.1183/13993003.02146-2021 · Cited by 38
“Likewise, results from the ongoing Pulmonary Fibrosis Biomarker cohort showed that longitudinal levels of type I and III collagen turnover were associated with progressive disease [55].”
Park, M. Y., Bae, S., Heo, J. A., Park, M., Kim, Y., Han, J., Jang, I., Yu, K., & Oh, J. (2023) · Clinical and Translational Science · doi:10.1111/cts.13518 · Cited by 15
“7) [25] 6 (100) [35] 6 (100) [32] 5 (83.”
Metadata
- Authors
- Jessen, H., Hoyer, N., Prior, T. S., Frederiksen, P., Karsdal, M. A., Leeming, D. J., Bendstrup, E., Sand, J. M. B., & Shaker, S. B.
- Venue
- Respiratory Research
- Published
- 2021-07-15
- Volume
- 22
- Issue
- 1
- Pages
- 205-205
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- OpenAlex
- W3163309330
- Cited by
- 65
- References
- 8
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12931-021-01801-0
- The paper
- Jessen, H., Hoyer, N., Prior, T. S., Frederiksen, P., Karsdal, M. A., Leeming, D. J., Bendstrup, E., Sand, J. M. B., & Shaker, S. B. (2021). Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Respiratory Research. https://doi.org/10.1186/s12931-021-01801-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.